Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir

References

• HajarizadehBGrebelyJDoreGJEpidemiology and natural history of HCV infectionNat Rev Gastroenterol Hepatol201310955356223817321
   PubMed Web of Science ®Google Scholar
• MaasoumyBWedemeyerHNatural history of acute and chronic hepatitis CBest Pract Res Clin Gastroenterol201226440141223199500
   PubMed Web of Science ®Google Scholar
• Hepatitis C Fact Sheet [homepage on the internet]World Health Organization Available from: http://www.who.int/mediacentre/factsheets/fs164/en/AccessedJune 1, 2017
   Google Scholar
• McdonaldSAHutchinsonSJPalmateerNEDecrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in ScotlandJ Hepatol201358346046623149064
   PubMed Web of Science ®Google Scholar
• HsuPCFedericoCAKrajdenMHealth utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infectionJ Gastroenterol Hepatol201227114915721679248
   PubMed Web of Science ®Google Scholar
• YounossiZHenryLSystematic review: patient-reported outcomes in chronic hepatitis C – the impact of liver disease and new treatment regimensAliment Pharmacol Ther201541649752025616122
   PubMed Web of Science ®Google Scholar
• McHutchisonJGWareJEHepatitis Interventional Therapy GroupThe effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivityJ Hepatol200134114014711211891
   PubMed Web of Science ®Google Scholar
• HassaneinTCooksleyGSulkowskiMThe impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis CJ Hepatol200440467568115030985
   PubMed Web of Science ®Google Scholar
• YounossiZMStepanovaMZeuzemSPatient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE studyJ Hepatol201461222823424713186
   PubMed Web of Science ®Google Scholar
• YounossiZMStepanovaMHenryLMinimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C)J Hepatol201460474174724333184
   PubMed Web of Science ®Google Scholar
• MarcellinFRouxPProtopopescuCDuracinskyMSpireBCarrieriMPPatient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issuesExpert Rev Gastroenterol Hepatol2017113110
   Web of Science ®Google Scholar
• EvonDMIncorporating patient-reported outcomes into hepatitis C virus treatment studiesClin Gastroenterol Hepatol20141281360136224534544
   PubMed Web of Science ®Google Scholar
• YounossiZMStepanovaMHenryLNaderFYounossiYHuntSAdherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimensMedicine20169528e415127428205
   PubMed Web of Science ®Google Scholar
• PatelKMchutchisonJGInitial treatment for chronic hepatitis C: current therapies and their optimal dosing and durationCleve Clin J Med200471Suppl 3S8S1215468611
   PubMedGoogle Scholar
• ShehabTMFontanaRJOberhelmanKMarreroJASuGLLokASEffectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practiceClin Gastroenterol Hepatol20042542543115118982
   PubMed Web of Science ®Google Scholar
• MravčíkVStradaLStolfaJFactors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature reviewPatient Prefer Adherence201371067107524204126
   PubMed Web of Science ®Google Scholar
• CopayAGSubachBRGlassmanSDPollyDWSchulerTCUnderstanding the minimum clinically important difference: a review of concepts and methodsSpine J20077554154617448732
   PubMed Web of Science ®Google Scholar
• JaeschkeRSingerJGuyattGHMeasurement of health status. Ascertaining the minimal clinically important differenceControl Clin Trials19891044074152691207
   PubMedGoogle Scholar
• SperlJHorvathGHalotaWEfficacy and safety of elbasvir/ grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trialJ Hepatol20166561112111927542322
   PubMed Web of Science ®Google Scholar
• WareJESF-36 health survey updateSpine200025243130313911124729
   PubMed Web of Science ®Google Scholar
• MchorneyCAWareJELuJFSherbourneCDThe MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groupsMed Care199432140668277801
   PubMed Web of Science ®Google Scholar
• SpiegelBMYounossiZMHaysRDRevickiDRobbinsSKanwalFImpact of hepatitis C on health related quality of life: a systematic review and quantitative assessmentHepatology200541479080015791608
   PubMed Web of Science ®Google Scholar
• FosterGRQuality of life considerations for patients with chronic hepatitis CJ Viral Hepat200916960561119674284
   PubMed Web of Science ®Google Scholar
• YounossiZMStepanovaMHenryLNaderFHuntSAn in-depth analysis of patient-reported outcomes in patients with chronic hepatitis c treated with different anti-viral regimensAm J Gastroenterol2016111680881627021197
   PubMed Web of Science ®Google Scholar
• YounossiZMStepanovaMSulkowskiMRibavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical TrialsClin Infect Dis20166381042104827444413
   PubMed Web of Science ®Google Scholar
• YounossiZMStepanovaMEstebanRSuperiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work ProductivityMedicine2017967e591428207507
   PubMed Web of Science ®Google Scholar
• YounossiZMStepanovaMFeldJSofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trialJ Hepatol2016651333926956698
   PubMed Web of Science ®Google Scholar
• YounossiZMStepanovaMAfdhalNImprovement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvirJ Hepatol201563233734525795586
   PubMed Web of Science ®Google Scholar
• YellenSBCellaDFWebsterKBlendowskiCKaplanEMeasuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement systemJ Pain Symptom Manage199713263749095563
   PubMed Web of Science ®Google Scholar
• YounossiZMStepanovaMSulkowskiMWylesDKottililSHuntSPatient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 studyLiver Int201737121796180428470938
   PubMed Web of Science ®Google Scholar
• CohenJStatistical Power Analysis for the Behavioral Sciences2nd edHillsdale, NJLawrence Earlbaum Associates1988
   Google Scholar
• BernsteinDKleinmanLBarkerCMRevickiDAGreenJRelationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patientsHepatology200235370470811870387
   PubMed Web of Science ®Google Scholar
• MaistatLGolovinSKravchenkoNKahnTBabikhinaKHepatitis C in Eastern Europe and Central Asia. Civil Society Response to the Epidemic2016 Available from: http://aph.org.ua/wp-content/uploads/2016/07/EECA_HCV_2016_EN.pdfAccessed September 21, 2017
   Google Scholar
• MaistatLKravchenkoNReddyAHepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countriesHepatol Med Policy2016219
   Google Scholar